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Objective 
To review our experience with cystic neoplasms of the pancreas at the Christian 
Medical College and hospital, Vellore during the period January 2001 to 
November 2008.  
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Review of literature  
Introduction 
Ductal adenocarcinoma is the most common tumor of the pancreas. There are 
other distinctive neoplasms of the pancreas, which display a wide range of 
symptoms, biological behavior, and outcomes. These include endocrine 
neoplasms, cystic tumors, solid pseudopapillary tumors, acinar cell carcinoma, 
squamous cell carcinoma, pancreatic lymphoma, and metastatic lesions of the 
pancreas. These tumors are becoming more frequently recognized and 
documented in literature, and at earlier stages, due to the increased sensitivity 
and utilization of non-invasive diagnostic imaging. The correct identification and 
treatment of these neoplasms of the pancreas is becoming increasingly important. 
 
Pancreatic cystic neoplasms are composed of a variety of neoplasms with a 
range of malignant potential.  The classification of these tumors has become 
clear only in the past few years [1]. Since first identified by Becourt in 1830, the 
major unsolved issue has been arriving at definite preoperative diagnosis [1]. 
When a cystic lesion of the pancreas is detected, the most important distinction 
to be made is between a cystic neoplasm and a pancreatic pseudocyst. Fifteen 
percent of pancreatic cysts are neoplastic; malignant, or benign. Distinguishing 
between a cystic neoplasm and a pseudocyst is important to avoid 
mismanagement of a cystic neoplasm [2]. With proper surgical treatment, cystic 
neoplasms are one of the few curable tumors of the pancreas.  
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Classification 
Pseudocysts make up the majority of all cystic lesions of the pancreas, the 
remainder comprising cystic tumors and true cysts (true cysts accounting for a 
very small percentage of these lesions).   
Pancreatic cysts can be classified based on the presence and type of cyst lining 
at the microscopic level [3]:  
Pseudocysts (no lining) 
- Conventional pseudocysts 
- Paraduodenal wall cyst (cystic dystrophy) 
- Infection-related pseudocysts 
 
Cysts with mucinous epithelium 
- Intraductal papillary mucinous neoplasms and intraductal oncocytic papillary 
neoplasms 
- Mucinous cystic neoplasms 
- ‘Mucinous non-neoplastic cysts’, ‘mucoceles’ and ‘retention cysts’ 
 
Serous (clear-cell) cystic tumors 
- Serous cystadenoma 
- VHL-associated pancreatic cysts 
- Serous cystadenocarcinomas 
 
Squamous-lined cysts 
- Lymphoepithelial cysts 
- Epidermoid cysts within intrapancreatic accessory spleen 
- Dermoid cysts 
- Squamoid cyst of pancreatic ducts 
 
Cysts lined by acinar cells 
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- Acinar cell cystadenocarcinomas 
- Acinar cell cystadenomas (cystic acinar transformation) 
 
Endothelial-lined cysts 
- Lymphangiomas 
 
Degenerative or necrotic changes in solid tumors 
- Solid-pseudopapillary tumor  
- Cystic change in ordinary ductal adenocarcinoma 
- Cystic pancreatic endocrine neoplasia (islet cell tumors) 
- Cystic change in other invasive carcinomas 
- Cystic mesenchymal neoplasms 
 
Other rare cystic lesions 
- Cystic hamartomas 
- ‘Enterogenous’ (congenital; duplication) cysts and duodenal diverticula 
- Endometriotic cyst 
- Secondary tumors 
- Congenital or developmental cysts 
- Others 
- Unclassified cysts 
 
 
The World Health Organization classified cystic neoplasms of the pancreas in 
1996:  
[4] 
 
Serous microcystic adenoma (SCA) 
Serous oligocystic adenoma 
Serous cystadenocarcinomas 
 
Mucinous cystadenoma (MCN) 
Mucinous cystic neoplasm - borderline 
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Mucinous cystadenocarcinomas 
- Non-invasive 
- Invasive 
 
Intraductal papillary mucinous neoplasm (IPMN) 
Intraductal papillary mucinous adenoma 
Intraductal papillary mucinous neoplasm - borderline 
Intraductal papillary mucinous carcinoma 
- Non-invasive 
- Invasive 
 
Solid pseudopapillary tumors (SPT) 
 
Cystic neoplasms of the pancreas, classified according to origin 
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Incidence 
 
Cystic tumors constitute 10% of cystic lesions of the pancreas, showing all 
stages of cellular differentiation from benign to highly malignant tumors. Benign 
(serous and mucinous) cystadenomas and cystadenocarcinomas constitute 75% 
of these cystic tumors. These cystic neoplasms account for 1-10% of all 
pancreatic malignancies [5]. The incidence of radiologically detected pancreatic 
cystic neoplasms in screening varied from 0.2% when ultrasonography was used 
to 0.7% in a study using CT and MRI scans [6]. 
Serous cystic neoplasms predominantly affect women (65%), with an average 
age of 62 years (range 35-84 years) [7]. They account for 32-39% of cystic 
tumors of the pancreas [8]. Mucinous cystic neoplasms also affect predominantly 
women (>95%), with an average age of 53 years (range 19-82 years) [9]. They 
constitute 10-45% of cystic pancreatic neoplasms. Together with the above two, 
intraductal papillary mucinous neoplasms of the pancreas (IPMNs) accounting for 
21-33%, comprise the three most commonly encountered tumors [8]. IPMNs 
occur a little more commonly in males at an average age of 65 years. Solid 
papillary epithelial neoplasia (SPENs) are tumors that predominantly occur in 
females in the third to fourth decade of life [8]. Non-functioning islet cell tumors 
(NFITs) with cystic degeneration occur at an average age of 53 years. Acinar cell 
cystadenocarcinoma most commonly occurs in males and constitutes <1% of 
cystic tumors [8].  
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Clinical features 
 
Up to 40-75% of patients with cystic pancreatic tumors are asymptomatic, with 
the majority being detected incidentally on imaging modalities [10]. When the 
lesion is symptomatic, the patient may present with recurrent pancreatitis, 
chronic abdominal pain, or jaundice. Symptoms are a result of pressure effects 
and are more common in mucinous lesions - the incidence of symptoms 
correlating with the risk of malignancy [11]. The most commonly encountered 
symptoms are abdominal pain, weight loss and nausea [12]. The less common 
symptoms are constipation, diarrhea, abdominal distension, fatigue, early satiety 
and, in the rare event of functioning tumors, the patient may show signs of 
hypoglycemia [13].  Jaundice, as a symptom, is uncommon in serous neoplasms 
even if the lesion is of a large size. In contrast, it is seen in 25-54% patients with 
mucinous tumors in the head of the gland [9]. A patient presenting with a large 
lesion in the head and neck of the pancreas without jaundice, should arouse the 
suspicion of a cystic neoplasm. A prior history of pancreatitis is generally 
confirmatory of pseudocysts, although the occasional cystic neoplasm may give 
rise to an attack of pancreatitis following partial duct obstruction. Bleeding-related 
complications secondary to gastric involvement, portal hypertension, hemobilia or 
hemosuccus pancreaticus, can be seen in malignant mucinous neoplasms [14].  
IPMNs, when symptomatic, present with signs of chronic pancreatitis and 
pancreatic insufficiency, i.e. pain, steatorrhea, weight loss or diabetes. They can 
also present as acute or recurrent pancreatitis. Diabetes is found to be 
associated with mucinous tumors, especially those that are malignant [15]. Rare 
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associations with Peutz-Jeghers and Zollinger Ellison syndrome have been 
described. On examination, a palpable mass may be detected in cases of 
malignant mucinous cystic lesions [14]. 
 
Pancreatic pseudocysts 
Pancreatic pseudocysts comprise >70% of all cystic lesions within the pancreas. 
Pancreatic pseudocysts are collections arising from around the pancreas, which 
lack an epithelial lining, and they occur following acute pancreatitis, chronic 
pancreatitis or secondary to pancreatic trauma. Pseudocysts normally contain 
necrotic fat and a mixture of necrotic cells, including neutrophils surrounded by 
granulation tissue, which eventually matures to form a fibrotic pseudocapsule. 
Pseudocysts can present in various ways ranging from abdominal pain, gastric 
outlet obstruction, obstructive jaundice, nausea or sepsis secondary to infection. 
Hemorrhage complicates only 5% of the pancreatic pseudocysts but carries with 
it a mortality of 40%. The cause of bleeding is due to pressure erosion of nearby 
blood vessels by the pseudocyst; the arteries usually affected are the splenic, 
gastroduodenal and superior pancreaticoduodenal arteries. The diagnosis of a 
pseudocyst is usually straightforward, with a clear history of either acute or 
chronic abdominal pain, or associated abdominal trauma. While pseudocysts 
have no malignant potential, many cystic neoplasms of pancreatic origin may 
mimic pseudocysts. Case reports of cystadenomas, papillary cystic tumors and 
giant cell tumors of the pancreas all misdiagnosed as pseudocysts are described 
in literature [16-18]. For this reason, proper sampling of pseudocysts is essential 
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and should consist of the cyst wall biopsy during open procedures or cyst 
contents during minimal access drainage procedures.   Up to 65% of the 
pseudocysts will have communication with the pancreatic ducts. Aspirated 
pseudocyst content will appear ‘prune juice’ in colour macroscopically (due to 
altered blood and pancreatic juice) typically with a high amylase, low viscosity 
and cytology consistent with an inflammatory origin.  Pancreatic pseudocysts 
arising after acute pancreatitis can often be managed conservatively, whereas 
the thicker-walled pseudocysts arising as a feature of chronic pancreatitis 
frequently require drainage.  
 
Pseudocysts which have not regressed or have increased in size may require 
surgical drainage and a variety of different methods have been described 
including open/laparoscopic pancreaticocystgastrostomy or 
pancreaticocystjejunostomy, percutaneous aspiration and drainage or 
endoscopic transmural or transpapillary drainage. Pseudocysts > 10 cm in size 
(associated with an increased risk of complications such as bleeding and 
infection), cysts persisting for > 6 weeks and symptomatic cysts are indications 
for drainage [19]. In recent years, open drainage of pancreatic pseudocysts has 
been replaced by laparoscopic and endoscopic techniques. A recent systematic 
review of 19 reported cohort series of laparoscopic drainage and 25 cohort series 
of endoscopic drainage of pseudocysts revealed no significant differences in 
success rates, complication rates, mortality rates or re-intervention (98.3 vs. 
80.8%, 4.2 vs. 12%, 0 vs. 0.4%, 0.8 vs. 0.2% respectively) [20]. However, the 
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size of pseudocysts drained laparoscopically was significantly greater (12 vs. 7 
cm) and the recurrence rate significantly higher for the endoscopic approach 
(14.4 vs. 2.5% for the laparoscopic approach). 
 
 
 
 
 
 
 
Differentiation of a pseudocyst from a cystic neoplasm 
of the pancreas 
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Pathology 
Mucinous cystic neoplasms are presumably de novo cystic tumors (unlike 
IPMNs which give rise to cystic dilatation of native ducts), and they are 
characterized by an ovarian type of stroma.  Macroscopically, these neoplasms 
are composed of large multilocular cysts ranging in size from one to several 
centimeters. The cysts have thick fibrotic walls. Unless there is fistula formation, 
the cysts do not visibly communicate with the pancreatic ductal system. The wall 
of the cysts may have velvety papillations, appear trabeculated, and thickened. 
The cyst contents are often mucoid; hemorrhagic or a more watery consistency 
may also be noted. Solid areas within the neoplasm should be sampled 
extensively for microscopic examination, as they may harbor an invasive 
component. 
 
Mucinous cystic neoplasms of the pancreas are morphologically similar to 
mucinous cystic neoplasms that occur in the retroperitoneum, ovary, and liver. 
This resemblance includes the presence of a distinctive stroma (referred to as 
ovarian-like) around the cysts which is a very common and an entity-defining 
feature of these neoplasms. There are two hypotheses on the origin of a 
neoplasm in the pancreas with ovarian-type stroma. The first hypothesis is that 
these neoplasms arise from rests of embryologic ovarian tissue deposited in the 
pancreas. This hypothesis is supported by the close proximity of the left ovarian 
primordium to the tail of the pancreatic anlage in fetal life. The second hypothesis 
is that the stroma represents a recapitulation of periductal fetal mesenchyme, the 
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primitive mesenchyme seen around the pancreatic and hepatic ducts in the 
developing fetus [21]. Regardless of its origin, it is clear that this stroma is 
hormone sensitive; it is often admixed with luteal-type cells and it regularly 
expresses progesterone receptors.  
 
Mucinous cystic neoplasm, gross appearance 
 
The cysts in mucinous cystic neoplasms are lined by tall, columnar, mucin-
producing epithelium, which may exhibit gastric foveolar-type intracellular mucin 
or goblet cells. Scattered neuroendocrine cells are present in the majority of 
cases and they can be demonstrated by immunohistochemical labeling for 
neuroendocrine markers such as chromogranin and synaptophysin. The 
epithelium in the predominantly cystic and adenoma components of MCNs are 
virtually indistinguishable from those of IPMNs. The papillary components, 
however, show some differences. MCN papillae do not typically have the full-
blown villous adenoma-like appearance and diffuse MUC2/CDX2 expression 
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characteristic of the ‘intestinal’ (darkcell, columnar-cell) subset of IPMNs. Instead, 
they often show MUC1 expression similar to the pancreatobiliary subtype of 
IPMNs. Some mucinous cystic neoplasms have purulent contents and these may 
be misdiagnosed as pseudocysts both intraoperatively as well as 
histopathologically especially if the epithelium is denuded, and the remaining 
ovarian stroma resembles the granulation tissue of pseudocysts. Inflammation 
may also impart a more complex architecture to an otherwise simple mucinous 
cystic neoplasm and raise the suspicion of malignancy. Mucinous cystic 
neoplasms can show a wide range of cytologic and architectural atypia. Some 
are histologically bland, with uniform, basally oriented nuclei, and minimal 
architectural atypia, while others exhibit prominent papillary proliferations that 
form intraluminal polypoid masses with cribriform architecture and substantial 
cytologic atypia.  
 
Mucinous cystic neoplasm, microscopic appearance 
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Patients with completely resected mucinous cystic neoplasms without atypia 
(mucinous cystadenomas) are almost always cured. Mucinous cystic neoplasms 
with moderate atypia are classified as mucinous cystic neoplasms with moderate 
dysplasia, while those with significant architectural and cytologic atypia are 
classified as mucinous cystic neoplasm with carcinoma in situ. Patients with 
these latter two grades of noninvasive mucinous cystic neoplasms are also often 
cured if their tumors are resected completely.  If an invasive carcinoma is present, 
the neoplasm should be classified as a mucinous cystadenocarcinoma. The 
invasive carcinomas that arise in association with mucinous cystic neoplasms are 
usually tubular/ductal type. Interestingly, these have been found to pursue a 
more indolent course than ductal adenocarcinoma.  
 
Serous cystadenoma is a benign neoplasm composed of uniform cuboidal 
glycogen-rich epithelial cells that form small cysts containing serous fluid. Serous 
cystadenomas are the prototypical and almost sole example of microcystic 
pancreatic neoplasms. In fact, the gross appearance of most serous 
cystadenomas—numerous, tightly packed small cysts and a stellate scar, 
creating a sponge-like appearance—is diagnostic of the entity. Serous 
cystadenomas usually present as relatively large masses measuring up to 25 cm, 
mostly in the body or tail of the pancreas. 
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Serous cystadenoma, macroscopic appearance 
Microscopically, these neoplasms have distinctive morphologic features. The 
cells lining the small cysts have clear cytoplasm, well-defined cytoplasmic 
borders, and small, round uniform nuclei with dense, homogeneous chromatin. 
Serous cystadenomas are presumed to arise from the centroacinar cell-
intercalated duct system. They are negative for mucin stains, and the glycogen 
can be highlighted by the PAS stain.  
 
Histopathology of serous cystadenoma 
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Intraductal Papillary Mucinous Neoplasms (IPMNs) are characterized by 
cystic dilatation of pancreatic ducts in which an intraductal proliferation of 
neoplastic mucin-producing cells is usually arranged in papillary patterns. The 
papillae may range from microscopic to large nodular masses. Mucin production 
by the neoplastic cells is usually associated with intraluminal mucin secretion 
which leads to cystic dilatation of the ducts, and at times, to mucin extrusion from 
the ampulla of Vater, a finding that is virtually diagnostic of IPMN. Depending 
upon the location of the primary process and subsequent mechanical changes in 
the ducts, IPMNs may present as a spectrum of multilocular cystic masses, 
villous/papillary nodules or with mucin extrusion from the ampulla.   Macroscopic 
examination of IPMNs is imperative for documenting involvement of the 
pancreatic ductal system and the distribution of the disease within the ductal 
system, especially since there are no basal or myoepithelial cells in pancreatic 
ducts to distinguish native ducts. In some cases, the IPMN primarily involves the 
main pancreatic duct, and in others the branch ducts. The latter have been 
referred to as ‘branch-duct’-type IPMNs. Some authors believe this variant is a 
biologically distinct entity, and therefore every attempt should be made during 
macroscopic examination to determine the distribution of the lesion. IPMNs may 
be localized, multicentric or, rarely, the entire ductal system may be involved.  
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Intraductal Papillary Mucinous Neoplasm, macroscopic appearance 
 
Microscopically, the cystically dilated ducts of IPMNs contain mucin-producing 
cells with various degrees of atypia. Papillae with three distinct morphologic 
patterns may be seen (1) intestinal, which is morphologically similar to that of 
colonic villous adenomas of the colon (2) pancreatobiliary, in which the papillae 
are more complex and are lined by cuboidal cells with prominent nucleoli and (3) 
gastric, rarely some papillas have gastric foveolar appearance. As this phenotype 
is also common in the nonpapillary areas of these tumors, it is also referred to as 
‘null’ type [22].  As advocated by the World Health Organization classification, 
noninvasive IPMNs are graded as adenoma, borderline-tumor and in situ 
carcinoma. Invasive adenocarcinoma, which is seen in less than 30% of cases is 
usually either of the colloid or tubular types. The former has been found to have 
indolent behavior, analogous to the colloid carcinomas of the breast, regardless 
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of whether it is associated with IPMN or not. 
 
IPMN, histopathology 
Solid Pseudopapillary Tumor (SPT) is the most recent name advocated by the 
WHO for a distinctive tumor type in the pancreas that often presents as a cystic 
mass.  For this reason it was previously (and is sometimes still) referred to as 
‘solid and cystic’, ‘solid and papillary’, ‘cystic and papillary’ and ‘papillary cystic’. It 
is now known that the cavities that form in SPTs are not ‘true’ cysts (there is no 
epithelial lining) but rather represent a necrotic/ degenerative process. The cystic 
areas often contain blood, necrotic debris, and clusters of foamy macrophages. 
In the cavity wall, characteristic morphologic features of these neoplasms include 
pseudopapillary architecture, hyaline globules, clusters of uniform cells mimicking 
neuroendocrine neoplasia, and grooved nuclei. 
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Gross pathology specimen of solid pseudopapillary neoplasm 
 
SPT is practically unique to the pancreas, with no close kindred in any other 
organ. It does not show clear-cut pathogenetic relationship to any of the cells 
normally found in the pancreas; there is no evidence for ductal, acinar, or frank 
endocrine differentiation.  Immunohistochemically, the neoplastic cells express 
nonspecific markers such as vimentin, CD56, alpha-1-antitrypsin and neuron-
specific (‘non-specific’) enolase; epithelial markers (keratins) can be focal or 
weak. Synaptophysin and NSE are commonly positive in SPTs; however 
chromogranin, the most specific endocrine marker, is typically negative. C-kit 
(CD117) expression has also been detected in a substantial portion of SPTs. The 
neoplastic cells consistently express progesterone receptors and also the beta 
form of estrogen receptors, suggesting a role for hormones in the evolution of 
these neoplasms.  
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Microscopic appearance of solid pseudopapillary neoplasm 
 
Imaging 
Ultrasound and Computerised Tomography 
Ultrasonography is a useful basic investigation as it can help differentiate a solid 
from a cystic lesion but it does not permit a complete characterization due to the 
presence of bowel gas that often obscures vision.  
 
CT scan is the most favored initial diagnostic test for cystic tumors of the 
pancreas. It is not only useful in the diagnosis but also helps in characterization 
of the lesion based on calcification of the cyst wall, septa, mural nodules and the 
findings suggestive of pancreatitis [23]. Enhanced CT with bolus injection of 
contrast medium and thin collimation is useful in differentiating SCA from 
mucinous cystic neoplasms (MCNs).  
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Appearances 
MCA - near water density unilocular or multilocular large cysts with enhancing 
walls and septa, and peripheral calcifications. 
Mucinous cystadenocarcinomas (MCACs) – thick walled (<2 mm) macrocysts, 
with septations, a solid component and a peripheral rim of calcifications.  
 
Mucinous cystadenoma shows a well-defined cyst in the body 
of the pancreas with internal septations and few macrocysts 
 
SCA - water, soft tissue or mixed density; poorly defined to thin, well defined 
capsule; multiple, small (<2 cm) well-defined cysts, central calcifications, and 
enhancement around microcysts after contrast administration.  
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Well-defined mass in the distal body of the pancreas with fine surface 
lobulations and a honeycomb pattern due to the presence of numerous 
microcysts, suggestive of serous cystadenoma 
 
IPMN - segmental or diffuse dilatation of the pancreatic ductal system. In side-
branch IPMN, involvement is limited to segmental ducts, resulting in a solitary 
cystic mass with an otherwise normal ductal system. 
 
Markedly dilated main pancreatic duct with pancreatic parenchymal atrophy - 
main duct IPMN 
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SPT - hypervascular peripheral solid components and central cystic. Atypical 
SCAs may appear as solid masses due to innumerable tiny cysts below the 
resolution of imaging equipment, or they may contain larger cysts similar to those 
of MCN. In this respect, some malignant cystic lesions mimic the appearance of 
a pseudocyst or other benign lesions.  
 
Peripheral calcification and enhancing nodules are seen along with cystic 
or necrotic areas – consistent with solid pseudopapillary tumor 
 
Magnetic Resonance Cholangio Pancreaticography 
MRI provides better characterization of the morphology of the cyst. In the case of 
IPMN it is being strongly advocated as the diagnostic modality of choice. Its 
advantage over ERCP stems from its ability to image the pancreatic duct 
anatomy/configuration and size, as filling of the side branch ducts may be 
obscured by intraductal mucin plugs in ERCP. Taouli et al [24] have shown that 
certain features of IPMN detected on MRI may actually indicate a higher 
probability of a malignancy, i.e. presence of a solid mass, main pancreatic duct 
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dilatation (<10 mm), diffuse or multifocal involvement, and attenuating or calcified 
intraluminal content.  
 
Endoscopic Retrograde Cholangio Pancreaticography (ERCP) 
ERCP plays a role in identifying the ductal anatomy and delineating the presence 
of any communication between the cyst and the duct that may be present in up to 
65% cases [25]. The main indication was the diagnosis of IPMN based on the 
demonstration of the communication of the tumor with the main duct and the side 
branches, as well as discharge of mucin from the ampulla. It is still an important 
investigation in the exceptional case of a patient with a cystic mass in the head of 
the pancreas very close to the main duct of Wirsung and where a differentiation 
between IPMN and even a serous cyst adenocarcinoma appears difficult and 
necessitates the demonstration of the relationship between the mass and the 
duct. 
 
Angiography 
The vascularity of the tumor and the peripancreatic region can be studied with 
the help of angiography that can help to differentiate a hypervascular tumor from 
hypovascular pseudocysts. We must remember that cystic tumors may also be 
hypovascular simulating pseudocysts. With the availability of better non-invasive 
diagnostic tests, the need for angiography has reduced.  
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Endoscopic Ultra Sonography (EUS) 
The main role for EUS in cystic pancreatic neoplasms is to provide detailed 
morphology of the cystic lesion (including the presence of intramural nodules in 
IPMN) and to guide fine-needle aspiration cytology (FNAC) of the lesion. It has 
its limitations in differentiating mucinous from non-mucinous cystic lesions due to 
its low sensitivity and specificity, i.e. 38.9% and 75.0%, respectively [12]. This 
also causes difficulty in differentiating benign from malignant lesions. 
 
Cyst fluid analysis 
The analysis of the cyst fluid obtained from EUS-guided aspiration provides 
valuable information if analyzed for biochemistry, tumor markers and not only 
cells as these aspirates tend to be paucicellular. In general, glycogen-rich cells 
are specific for serous cystadenoma, mucin-containing cells are seen in 
mucinous cystadenomas, and malignant cells are seen in mucinous 
cystadenocarcinomas [26]. Potential complications of FNA include spillage of 
malignant cells into the peritoneum, hemorrhage and injury to adjacent organs. 
The table below shows the various components that are analyzed and the 
quantities in which they are found in the various common neoplasia  
Component SCA MCN IPMN Pseudocyst 
Amylase Low Low High High 
CEA <5 >800 5-800 <5 
CA 19-9 <37 Variable Variable <37 
CA 15-3 Low High Low Low 
TAG 72 <3 3-137 High <5.7 
Malignant 
cells 
Absent Absent Absent Absent 
CA 125 Low Variable Low Low 
Viscosity Low High High Low 
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Positron Emission Tomography (PET) scan 
Sperti et al. [27] have suggested that 18-FDG PET may be better than CT and 
tumor marker assays in the preoperative evaluation of patients with cystic 
pancreatic lesions.  This is because a positive result strongly suggests 
malignancy, and hence warrants surgical treatment.  A negative result implies a 
benign lesion that may be treated by limited resection or, in selected high- risk 
patients, with biopsy, follow-up, or both.  
 
Management 
The treatment of cystic pancreatic tumors depends on the probable diagnosis, as 
the likelihood of malignancy is closely related to the type of histology. The 
possibility of malignancy in a serous cystic tumor is as low as 3%, while main 
duct IPMNs have a 70% chance of being malignant [28]. Mucinous cystic tumors 
can be best considered as premalignant.  
 
The need to operate on patients with lesions that are <3 cm is still controversial. 
While Sahani et al. [29] have found that lesions <3 cm are usually benign, Kiely 
et al. [13] have stressed the need for enucleation even in patients with lesions <2 
cm, as long as the patient can withstand the operation. This recommendation is 
based on a high incidence of false negatives seen in investigations. Allen et al. 
[30] in a recent large series of 539 cases spanning 10 years have concluded that 
selected patients with cystic lesions <3 cm in diameter and without a solid 
component may be followed radiographically with a  malignancy risk that 
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approximates the risk of mortality from resection. This is based on the premise 
that small mucinous lesions are unlikely to be malignant.  
 
The currently accepted guidelines are that for serous cystadenomas, an organ-
preserving resection should be carried out, although there are proponents of a 
conservative line of management. Accepted consensus is that lesions that are 
asymptomatic and/or <4 cm in size can be followed up at yearly intervals, while 
surgical treatment should be offered to patients with symptomatic lesions and 
tumors >4 cm, because they have been seen to grow at a rate of almost 1.98 
cm/year [31]. 
 
In the case of mucinous tumors, a more radical resection is advised. This is 
based on the understanding of their malignant potential. As these tumors usually 
occur in the fifth decade, the likelihood of a malignant transformation is also high. 
In the presence of predictors of malignancy, such as large tumor size, mural 
nodules and egg-shell calcification, spleen preserving techniques should be 
avoided to obtain a correct oncological lymph node dissection. 
 
In the case of IPMN, where the tendency is for the tumor to grow along the ducts 
rather than radially into the parenchyma, the resection margins must be 
examined by frozen section intraoperatively to confirm the clearance of the 
margins. The current recommendation is to resect all main duct and mixed 
variant IPMNs as long as the patient is a good surgical candidate with a 
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reasonable life expectancy [28]. Routine total pancreatectomy is not indicated 
and should be performed only for obvious extensive, but resectable, histologically 
confirmed disease involving the entire gland.  The issue of management of pure 
branch-type IPMNs remains to be resolved, with conflicting data on whether a 
conservative approach or an anatomic resection should be performed. The IAP 
consensus for management of IPMNs [28] has attempted to put some of these 
doubts to rest by recommending surgery for symptomatic lesions. However, they 
have added that other indications could include patients willing for surgery and 
unlikelihood of follow-up. This remains an option only if a safe pancreatic 
resection is available.  
 
Solid pseudopapillary tumors of the pancreas are best described as indolent and 
non-aggressive.  However, local and distant metastases are possible. Formal 
resection with curative margins is essential to ensure the best possible long-term 
survival. An aggressive approach would also appear to be justified regardless of 
tumor size or metastatic spread.  For lesions located at the pancreatic body and 
tail, segmental or distal pancreatectomy, with preservation of the spleen where 
possible, is recommended. In case of cystic masses that are malignant or 
potentially malignant in the head of the pancreas, pancreaticoduodenectomy is 
the preferred option, but enucleation can be performed if there is an accurate 
diagnosis of a benign lesion.  
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Tanaka et al. have described the indications for a ‘wait and see’ policy in MCNs 
and IPMNs which include [28]:  
1. Symptomatic cysts without main duct dilatation (<6 mm) 
2. Those without mural bodies 
3. Those <30 mm in size 
The ideal investigations for monitoring such patients would be CT or MRCP and 
EUS. 
The suggested interval between follow-up examinations would be: 
- yearly for lesions <10 mm in size 
- 6-12 monthly follow-up for lesions between 10 and 20 mm 
- 3-6 monthly follow-up for lesions >20 mm 
The interval can be lengthened after 2 years of stationary findings. Indications for 
giving up the conservative management would include the appearance of 
symptoms, and findings contrary to those listed above. 
 
Adjuvant treatment  
A few reports exist on the use of chemotherapy, and occasionally, radiotherapy 
in the adjuvant setting. The indications are evidence of tissue invasiveness in the 
pathological specimen, liver metastasis (chemoembolization), unresectable 
tumor (radiotherapy), large tumors (neoadjuvant chemotherapy to downsize the 
tumor for surgery), and with aneuploid neoplasms [14]. Sarr et al. have 
suggested a role for adjuvant treatment even in the absence of lymph node 
metastasis [32]. The role of chemoradiation, whether in the adjuvant or 
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neoadjuvant setting, requires more studies to prove the efficacy. Maire et al. [33] 
have suggested that in the absence of current evidence for adjuvant therapy in 
pancreatic cancer, patients with locally advanced malignant cystic neoplasms, 
especially IPMNs, should be included in the same protocols assessing adjuvant 
chemotherapy and radiotherapy regimens as patients with ductal 
adenocarcinoma. 
 
Prognosis 
The overall 5-year survival nears 100% for serous cystadenoma and even 
mucinous cystadenoma where the resection margins are clear and there is no 
evidence of transmural invasion [8, 10]. Even in IPMNs containing carcinoma, 5-
year survival is over 50% [34]. Solid pseudopapillary tumors have a cure rate of 
80%.  
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Details of the study 
Methods 
A retrospective review of the medical records of patients who underwent 
operative therapy for cystic neoplasms of the pancreas at the Christian Medical 
College and Hospital, Vellore from January 2001 through November 2008 was 
conducted. Medical records were examined for presenting signs and symptoms, 
diagnostic modalities, laboratory values, surgical procedure, pathologic features, 
and postoperative complications.  Data was entered into a standard proforma 
and analyzed. 
 
Study design  
Retrospective review 
 
Exclusion criteria  
1. Pancreatic pseudocyst 
2. Solid tumors of the pancreas   
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Results 
A total of 27 patients were identified who underwent operative therapy for 
pancreatic cystic neoplasms. Most were female (93%). 
Gender
7%
93%
Male
Female
 
 
Age  
Patients ranged from 17 years of age to 62 years.  The average age was 35 
years. Two-thirds of the patients were below 40 years of age.  
 
 
Age distribution 
9, 33%
18, 67%
<40 years
>40 years
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Age(yr)/Subtype SCA MCN SPT IPMN Others 
10-20 - - 2 - 1 
20-30 - 1 6 - 2 
30-40 - 2 3 - - 
40-50 - 5 - - 1 
>50 1 1 - 1 1 
 
Age-wise distribution of each sub-type of tumor 
 
Classification 
Mucinous cystadenoma and solid pseudopapillary tumor were the predominant 
subtypes in our series.  
Classification
9, 32%
11, 39%
1, 4%
1, 4%
6, 21%
SCA
MCN
IPMN
SPT
Others
 
  
Clinical features 
The duration of symptoms ranged from 2 months to 5 years. The average 
duration of symptoms was 19 months.  
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The neoplasm was incidentally detected on ultrasound in 8% of patients.  Eighty 
percent of patients had abdominal pain as the presenting symptom. Abdominal 
lump and vomiting were seen in a minority of patients. None of the patients had a 
previous history of pancreatitis. 
Symptom Number of patients (%) 
Abdominal pain 22 (81) 
Abdominal lump 4 (15) 
Nausea and vomiting 4 (15) 
Jaundice 2 (7.5) 
Acute abdomen 1 (3.7) 
Pancreatic exocrine deficiency 1 (3.7) 
Asymptomatic 2 (7.5) 
 
Symptoms
0
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Nausea and vomiting
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Pancreatic exocrine deficiency
Asymptomatic
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In about half the patients an abdominal lump was palpable. Two patients had 
splenomegaly.  
Abdominal lump (cm)
28%
16%
0%
56%
No
<3 
3 to 10
> 10 
 
Investigations 
Hemoglobin: 5 out of 27 (18%) patients had a hemoglobin value of < 10g%.  
Blood sugar: 2 patients (7.5%) were found to be diabetic at the time of 
presentation. 
Liver function tests in most patients were normal, except for elevated serum 
alkaline phosphatase levels in 7 (26%) patients.  
Serum amylase was only mildly elevated in 23% of patients (up to 497 U/L). 
Serum lipase levels were elevated, though not significantly, in 4 out of 8 patients 
in whom the investigation was done.  
Tumor markers: CA 19 – 9 was done in 13 patients. 3 patients had an abnormally 
high value, but all values were less than 1000. CEA was done only in 7 patients, 
with only 1 elevated value.  CA-125 was done in one patient suspected pre-
operatively to have an adnexal tumor.  
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Imaging 
Ultrasound was done in 6 (22%) patients. It was useful in differentiating a cystic 
neoplasm from a pseudocyst. CT scan of the abdomen was done in 23 out of 27 
patients.  The cyst size on CT scan was less than 3 cm in only 2 patients (8%).  
 
 
 
 
 
 
 
 
 
Location of cyst: Almost two-thirds of the lesions were found in the tail of 
pancreas. 
Location on CT scan
13%
4%
22%
61%
Head
Uncinate
Body
Tail 
 
Cyst size on CT scan (cm)
0
1
2
3
4
5
6
7
8
9
Cyst size (cm)
<3 
3 to 10 
>10
Not mentioned
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The characteristic features of macrocysts and rim calcifications were seen only in 
one patient. Cystic neoplasms were mistakenly diagnosed as pseudocysts in 4 
out of 23 patients (17%).  Accurate sub-typing of the cystic neoplasms was 
possible only in 5 out of 23 patients (21%).  Splenic vein thrombosis was an 
incidental finding in 3 patients. Two patients were wrongly diagnosed to have 
duodenal GIST (gastro intestinal stromal tumor) on imaging.  
 
Endoscopy  
Only 4 patients underwent upper gastrointestinal scopy as a part of evaluation; 
these were normal. The patient with IPMN had side viewing scopy which showed 
a gaping major papilla with mucin.  EUS was done in 3 patients, and a correct 
diagnosis was made in 1 patient. Cyst fluid was aspirated for analysis in only 1 
patient, showing scanty atypical cells.  
 
Operation Only one out of the twenty seven patients underwent an emergency 
procedure for ruptured cyst. 
Elective / emergency procedure
1
26
Emergency
Elective
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Type of operation  
The operation done for these tumors depended on the location. The majority of 
patients underwent distal pancreatectomy (80%).  The patient who had subtotal 
pancreatectomy required portal vein reconstruction (infiltration by tumor).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Distal pancreatectomy
15
1
2 2
0
2
4
6
8
10
12
14
16
1
Open
Laparoscopic
Lap converted open
Spleen sparing
Type of operation done
4, 15%
1, 4%
20, 73%
1, 4%
1, 4%
Whipple
Central
Distal
Subtotal
Others
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Operative findings 
 
The tumors were predominantly located in the tail of the pancreas. 
 
 
Intraoperative location
5
3
7
12
1
Head 
Neck 
Body 
Tail 
Multiple
 
 
 
The size of the tumor was measured at the time of the operation.  Sixty five 
percent of tumors were more than 10 cm in size. There were no tumors less than 
3 cm in size.  
Intraoperative size (cm)
0% 9%
17%
65%
9%
<3
3 to 5 
5 to 10
>10 
Not measured
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There was no evidence of metastases in any of the patients; none of the tumors 
were inoperable.  
 
Histopathology 
There were 3 malignant neoplasms in the series, accounting for 11% of patients.  
Benign vs. malignant
89%
11%
Benign
Malignant
 
 
On microscopic examination, the predominant subtype was solid pseudopapillary 
tumor. 
Subtype N 
Mucinous cystadenoma  7 
Mucinous cystadenoma borderline 1 
Mucinous cystadenocarcinoma 1 
Serous cystadenoma 1 
IPMN 1 
Solid pseudopapillary tumor 11 
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Acinar cell carcinoma 1 
Teratoma 1 
Others 3 
 
Histopathological subtypes
0
2
4
6
8
10
12
Mucinous cystadenoma
Mucinous cystadenoma
borderline
Mucinous
cystadenocarcinoma
Serous cystadenoma
IPMN
Solid pseudopapillary
tumour
Acinar cell carcinoma
Teratoma
Oth  
The margins were involved microscopically in only one case of serous 
cystadenoma.  
 
Complications  
Intra-operative 
One patient had an iatrogenic diaphragmatic rent intra-operatively, which was 
managed with closure and intercostal chest drainage.  
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Post-operative  
Complication N (%) 
Pancreatic fistula 2 (7.5) 
Intra-abdominal abscess 4 (15) 
Wound infection 3 (11) 
Hemorrhage 1 (3.7) 
Aspiration pneumonia 1 (3.7) 
Deep vein thrombosis 1 (3.7) 
Urinary tract infection 2 (7.5) 
Gram negative sepsis 1 (3.7) 
 
Complications
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
Pancreatic fistula
Intra-abdominal abscess
Wound infection
Hemorrhage
Aspiration pneumonia
Deep vein thrombosis
Urinary tract infection
Gram negative sepsis
 
There was no mortality.   
 
 
 
 48
Follow up 
Follow up was available in 21 patients. The mean duration of follow up was 12.1 
months.  (Range: 0.5 to 43 months).  One patient with mucinous cystadenoma 
had suspected recurrence at 13 months, and underwent re-excision.  
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Discussion 
There is only one other similar case series from India dealing with cystic 
neoplasms of the pancreas, published in 1992. This review has the largest 
number of cases reported in India.  
 
The patients were predominantly female, as expected. Unlike most other series, 
40% of patients had solid pseudopapillary tumors, which are usually rare. Most 
other series report  serous or mucinous cystadenomas as the commonest 
subtypes [1]. As these tumors are found in the 2nd and 3rd decades of life, the 
average age of the patients in our series was also less than expected.  
 
With the increasing use of diagnostic abdominal imaging, we would have 
expected a larger proportion of these lesions to be picked up incidentally. Current 
evidence indicates that 40-75% of these tumors are detected as an incidental 
finding on radiographic images [10]. This trend was not found in our series, with 
only 2 patients diagnosed on routine imaging. The most common abdominal 
symptoms were abdominal pain and abdominal lump; in accordance with most 
case series in Western literature [35]. Half the patients did not have a palpable 
abdominal lump at presentation.  
 
Routine hemogram and liver function tests did not contribute significantly towards 
a diagnosis. Serum amylase and lipase in all patients were not markedly 
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elevated, making a diagnosis of pseudocyst unlikely. Tumor markers were not 
helpful in differentiating among the various subtypes.  
 
As most of our patients are referred from another centre, ultrasound imaging was 
not performed routinely. CT scan was accurate in diagnosing a neoplasm in 83% 
of cases, but sub-typing was possible in only 21% of patients. This may be due to 
the unfamiliarity of the junior radiologists with pathognomonic signs and recent 
terminology associated with cystic neoplasms of the pancreas.  Only 10% of 
tumors were less than 3 cm in size, hence amenable for a trial of non-operative 
management. Most tumors <3 cm are detected incidentally. Hence with the 
increasing use of abdominal imaging, the proportion of cystic neoplasms for 
which conservative management is an option will increase in future [30].  
 
The use of endoscopy and endoscopic ultrasound has only recently been added 
to the diagnostic armamentarium with regards to these cystic tumors. Only 3 
patients underwent EUS in this series, but these were the more recent cases. 
EUS is a useful and necessary mode of investigation and will see more 
widespread use in future. All the recent reviews advocate the routine use of EUS 
in the management algorithm for indeterminate cystic lesions of the pancreas 
[36]. EUS along with cyst fluid analysis for amylase, CEA and viscosity is able to 
differentiate the various subtypes of cytic neoplasms [14]. 
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All patients in our series were those selected for operative management. As the 
majority of lesions were located in the tail of the pancreas, distal pancreatectomy 
was the most frequent operation performed. Intra-abdominal collection and 
wound infection were the most common post-operative complications. Sheehan 
et al. [35] in their large series found pancreatic fistula to be their commonest 
complication, followed by wound infection.  
 
There was no perioperative mortality. As mentioned earlier, one patient had 
suspicion of recurrence of mucinous cystadenoma on radiological imaging, but 
the operative specimen showed no features of recurrence on microscopy.  
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Limitations of the study 
1. The nomenclature and terminology associated with these tumors as per 
the WHO classification was not strictly followed during reporting of 
radiological imaging and histopathological specimens. 
 
2. Follow up was not available in 6 patients.  
 
3. As most of our patients are referred from other centers, the diagnosis of a 
cystic neoplasm is already made when the patient visited this hospital.  
 
4. The use of EUS and EUS guided FNAC as a routine diagnostic modality 
has only recently become available in this institution.  
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Conclusions 
1. Cystic neoplasms of pancreas are relatively rare tumors, predominantly 
seen in the female population in the 4th to 5th decades of life.  
 
2. Clinical presentation is non-specific and CT scan abdomen is the imaging 
modality of choice to diagnose these lesions.  
 
3. Given the relatively late presentation of our subset of patients, non-
operative management is usually not an option.  
 
4. The extent of resection depends on the histological subtype of the lesions, 
but recurrence is rare and the prognosis is uniformly good.  
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Cystic neoplasms of the pancreas - proforma 
 
Serial No.  
Name 
Age 
Gender 
Hospital Number  
Diagnosis 
Presenting complaints     Duration 
Asymptomatic 
Abdominal lump 
Pain 
Jaundice 
Nausea 
Vomiting 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm  
 
Investigations 
 Hb  
 Serum creatinine 
 Glucose  AC 
   PC  
Serum amylase 
 Serum lipase 
 LFT 
 Tumor markers 
  CA 19-9 
  CEA 
  CA-125 
 
 USG  
  Presentation  
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Location 
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
CT  
  Presentation 
  Cyst size 
Location  
  Macrocystic 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant 
  Radiologist’s opinion 
 
 Endoscopy  
  Ampulla 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
  
 
Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase  
 
Operation done 
 
Operative findings 
 Location 
 Size 
 Benign / malignant 
 61
 Inoperable 
   
Histopathology  
 Type 
 Benign/malignant 
 Margin 
Spleen 
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
 Gram negative sepsis 
Death 
 
Follow up  
 Duration 
 Recurrence 
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Cystic neoplasms of the pancreas 
 
Serial No. 1 
Name Sk. Melon  
Age 20 
Gender M 
Hospital Number 132409D  
Diagnosis Retention cyst  
Presenting complaints     Duration 
Asymptomatic discharging sinus left flank 4 y 
following I and D  
Pain 
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm  
 
Investigations 
 Hb 12.4 
 Serum creatinine 1.0 
 Glucose  AC 75 
   PC 102  
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Serum amylase 244 
 Serum lipase 76 
 LFT 0.5/0.2/9.1/3.7/30/53/304 
 Tumor markers 
  CA 19-9  
  CEA 
  CA-125 
 
 USG  
  Presentation  
Location 
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
 
 
CT  
  Presentation 
  Cyst size multiple 6 cm  
Location head and tail   
  Marcocystic 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant 
  Radiologist’s opinion sequelae of acute pancreatitis  
 
 Endoscopy  
  Ampulla 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
 64
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
Operation done Sinusogram proceed laparotomy and drainage of 
peripancreatic abscesses 
 
Operative findings 
 Location Head and tail 
 Size 
 Benign / malignant 
 Inoperable 
   
Histopathology  
 Type Distended duct/retention cyst 
           Keratinous debris    
 Benign/malignant 
 Margin 
Spleen 
Immune staining 
 
Post-operative complications 
 Pancreatic fistula present  
 Intra-abdominal abscess present 
 Wound infection 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
  
Death 
 
Follow up  
 Duration Nil 
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 Recurrence 
  
   
   
 
 
 
 
 
Cystic neoplasms of the pancreas 
 
Serial No. 2 
Name Monowara Begum 
Age 27 
Gender F 
Hospital Number  275688D 
Diagnosis Solid pseudopapillary tumor 
Presenting complaints     Duration 
Asymptomatic 
Pain upper abdominal     4 y 
Jaundice 
Nausea 
Vomiting present      4 y  
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm  
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Investigations 
 Hb 11.2  
 Serum creatinine 1.0 
 Glucose  AC 110 
   PC  
Serum amylase  
 Serum lipase 
 LFT 
 Tumor markers 
  CA 19-9 
  CEA 
  CA-125 
 
 USG   
  Presentation  
Location 
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 
 
 
 
CT  
  Presentation mass tail of pancreas  
  Cyst size 
Location  
  Marcocystic 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant 
  Radiologist’s opinion 
 
 Endoscopy  
  Ampulla 
 67
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
 
Operation done Laparoscopic converted open distal pancreatectomy and 
splenectomy 
 
Operative findings 
 Location Tail 
 Size 10 x 8 cm solid tumor 
 Benign / malignant benign 
 Inoperable   
   
Histopathology  
 Type Solid pseudopapillary tumor 
 Benign/malignant Benign 
 Margin Free 
Spleen Congestion 
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 68
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
  
Death 
 
Follow up  
 Duration 15 d  
 Recurrence no 
  
   
   
 
 
 
 
 
 
Cystic neoplasms of the pancreas 
 
Serial No. 5 
Name Antara Ghosh  
Age 26 
Gender F 
Hospital Number 264608D 
Diagnosis Solid papillary epithelial neoplasm 
Presenting complaints     Duration 
Asymptomatic 
Pain 
Lump upper  abdomen     3 m 
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue  
Early satiety 
Pancreatic exocrine insufficiency 
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Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm 10 x 10 cm smooth  
 
Investigations 
 Hb 13.3 
 Serum creatinine 1.0 
 Glucose  AC 
   PC  
Serum amylase 
 Serum lipase 
 LFT 0.6/0.2/8.4/4.6/16/18/111 
 Tumor markers 
  CA 19-9 5.73 
  CEA 0.469 
  CA-125 
 
 USG  
  Presentation  
Location 
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 
 
 
 
CT  
  Presentation 
  Cyst size  
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Location near head 
  Marcocystic  
  Rim calcification 
  Neoplasm x pseudocyst neoplasm 
  Serous x mucinous 
  Benign x malignant  
  Radiologist’s opinion GIST  
 
 Endoscopy  
  Ampulla normal 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
Adjacent mass-  large mass with well defined margins anterior 
wall D2,  hypoechoic,  Separate from duodenum and pancreas.  
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
Operation done Whipple procedure  
 
Operative findings 
 Location Head  
 Size 12 x 10 cm  
 Benign / malignant benign  
 Inoperable 
   
Histopathology  
 Type Solid papillary epithelial neoplasm  
 Benign/malignant Benign 
 Margin Free 
Spleen 
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Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess present  
 Wound infection 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis present  
 Delayed gastric emptying 
 Urinary tract infection yes  
 Reoperation 
  
Death 
 
Follow up  
 Duration 4m  
 Recurrence no 
  
   
   
 
 
 
 
 
Cystic neoplasms of the pancreas 
 
Serial No. 6 
Name Gitanjali Dutta 
Age 43 
Gender F 
Hospital Number 225911D 
Diagnosis Mucinous cystic neoplasm 
Presenting complaints     Duration 
Asymptomatic 
Pain 
Lump       1 yr 
Jaundice 
Nausea      1 yr 
 72
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 7 x 7 cm LUQ Smooth  
  >10 cm  
 
Investigations 
 Hb 10.1 
 Serum creatinine 0.9 
 Glucose  AC 92 
   PC 82 
Serum amylase 
 Serum lipase 239 
 LFT0.9/0.2/8.3/4.2/19/10/92 
 Tumor markers 
  CA 19-9 48.6 
  CEA 3.36 
  CA-125 
 
 USG  
  Presentation  
Location 
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
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CT  
  Presentation  
  Cyst size 10 x 8.5 x 7 cm 
Location Body and tail   
  Marcocystic 
  Rim calcification 
  Neoplasm x pseudocyst not sure   
  Serous x mucinous 
  Benign x malignant  
  Radiologist’s opinion neoplasm less likely 
Splenic vein thrombosed 
 
 Endoscopy  
  Ampulla 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
Adjacent mass - large cyst in relation to  body and tail with 
debris 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 231 
  CA 19-9 >1000 
  CA-125 
  Amylase 9938 
Operation done Distal pancreatectomy, splenectomy and cholecystectomy 
 
Operative findings 
 Location Tail 
 Size 12 x 10 
 Benign / malignant benign  
 Inoperable 
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Histopathology  
 Type Mucinous cystic neoplasm 
 Benign/malignant benign 
 Margin  
Spleen congestion  
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
  
Death 
 
Follow up  
 Duration 14 days 
 Recurrence no 
  
   
   
 
 
 
 
 
Cystic neoplasms of the pancreas 
 
Serial No. 7  
Name Dipa Saha 
Age 24 
Gender F 
Hospital Number 126507D 
Diagnosis Solid cystic papillary neoplasm  
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Presenting complaints     Duration 
Asymptomatic      yes 
Pain 
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm 10 x 10 cm  
 
Investigations 
 Hb 6.7 
 Serum creatinine 0.7 
 Glucose  AC 87 
   PC 114  
Serum amylase  
 Serum lipase 
 LFT 0.5/0.2/9.0/4.4/45/34/95 
 Tumor markers 
  CA 19-9 7.2 
  CEA 
  CA-125 
 
 USG  
  Presentation  Yes  
Location 
Cyst 
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  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 
CT  
  Presentation 
  Cyst size Heterogenously enhancing 10 x 10.5 cm  
Location body 
  Marcocystic 
  Rim calcification present  
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant 
  Radiologist’s opinion SPEN / neuroendocrine tumor  
 
 Endoscopy  
  Ampulla 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
Operation done Distal pancreatectomy and splenectomy  
 
Operative findings 
 Location body 
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 Size 20 x 15 cm  
 Benign / malignant benign 
 Inoperable 
   
Histopathology  
 Type Solid papillary epithelial neoplasm 
 Benign/malignant benign 
 Margin free 
Spleen congestion 
Immune staining  
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection 
 Hemorrhage 
 Aspiration pneumonia left lower lobe  
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
  
Death 
 
Follow up  
 Duration Nil  
 Recurrence 
  
   
   
 
 
 
 
 
Cystic neoplasms of the pancreas 
 
Serial No. 8 
Name Sussy Thomas 
Age 40 
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Gender F 
Hospital Number 415071C 
Diagnosis Mucinous cystadenoma  
Presenting complaints     Duration 
Asymptomatic 
Pain low back      2 yrs 
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm  
 
Investigations 
 Hb 10.3  
 Serum creatinine 0.7 
 Glucose  AC 
   PC 100 
Serum amylase 128 
 Serum lipase 
 LFT 0.6/0.2/7.6/4.3/29/21/68 
 Tumor markers 
  CA 19-9 <2.50 
  CEA 
  CA-125 
 
 USG  
 79
  Presentation  
Location 
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 
CT  
  Presentation 
  Cyst size 
Location  
  Marcocystic 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant 
  Radiologist’s opinion 
 
 Endoscopy  
  Ampulla 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
Operation done Distal pancreatectomy and splenectomy  
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Operative findings 
 Location body and tail  
 Size 6 x 5 cm  
 Benign / malignant benign  
 Inoperable 
   
Histopathology  
 Type mucinous cystadenoma  
 Benign/malignant benign  
 Margin  
Spleen congestion 
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
  
Death 
 
Follow up  
 Duration 3years 
 Recurrence no  
  
   
   
 
 
 
 
 
Cystic neoplasms of the pancreas  
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Serial No. 9  
Name Arpita Kundu 
Age 21 
Gender F 
Hospital Number 724621c 
Diagnosis Solid papillary epithelial neoplasm 
Presenting complaints     Duration 
Asymptomatic 
Pain Upper abdominal     3 m  
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm 11 x 9 cm epigastric 
 
Investigations 
 Hb 10.4 
 Serum creatinine 0.8 
 Glucose  AC 
   PC  
Serum amylase 105 
 Serum lipase 57 
 LFT  
 Tumor markers 
  CA 19-9 <2.5 
  CEA 
 82
  CA-125 
 
 USG  
  Presentation  
Location ? 
Cyst 12.5 x 10 x 9 cm  
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component predominantly solid with few cystic areas 
  Papillary 
  
 
CT  
  Presentation 
  Cyst size 13 x 12 x 7 cm  
Location body and tail  
  Marcocystic 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant 
  Radiologist’s opinion leiomyoma/GIST 
    Splenic vein thrombosis 
 
 Endoscopy  
  Ampulla 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
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  CA 19-9 
  CA-125 
  Amylase 
 
Operation done Distal pancreatectomy and splenectomy  
 
Operative findings 
 Location body  
 Size 15 x 10 cm 
 Benign / malignant 
 Inoperable 
   
Histopathology  
 Type Solid pseudopapillary neoplasm 
 Benign/malignant benign 
 Margin  
Spleen congestion 
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
  
Death 
 
Follow up  
 Duration 23 m  
 Recurrence no 
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Cystic neoplasms of the pancreas 
 
Serial No. 10 
Name Paramita Sen Gupta Mittal  
Age32 
Gender F 
Hospital Number 827789C 
Diagnosis Boderliine mucinous cystic neoplasm 
Presenting complaints     Duration 
Asymptomatic 
Pain Left flank     1 year  
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm  
 
Investigations 
 Hb 10.5 
 Serum creatinine 1.0 
 Glucose  AC 96 
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   PC  
Serum amylase  
 Serum lipase 
 LFT 0.5/0.2/7.6/3.5/23/35/138 
 Tumor markers 
 CA 19-9 
  CEA 
  CA-125 
 
 USG  
  Presentation  
Location body and tail  
Cyst 2.6 x 2.6 cm  
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
CT  
  Presentation 
  Cyst size 32 x 31 mm  
Location body 
  Marcocystic 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant 
  Radiologist’s opinion 
 
 Endoscopy  
  Ampulla 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
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 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
Operation done Laparoscopic converted open distal pancreatectomy  
 
 
Operative findings 
 Location body 
 Size 3 x 3 cm  
 Benign / malignant 
 Inoperable 
   
Histopathology  
 Type borderline mucinous cystic neoplasm 
 Benign/malignant borderline 
 Margin free 
Spleen congestion 
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection Superficial wound infection 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation  
  
Death 
 
Follow up  
 
 Duration 1 year 
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 Recurrence no  
  
   
   
 
 
 
 
 
Cystic neoplasms of the pancreas 
 
Serial No. 11 
Name Anjali Sema 
Age 41 
Gender F 
Hospital Number 960853C 
Diagnosis Mucinous cystadenoma 
Presenting complaints     Duration 
Asymptomatic 
Pain RUQ       1 yr 
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm  
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Investigations 
 Hb 8.4 
 Serum creatinine 0.7 
 Glucose  AC 99 
   PC 105  
Serum amylase  
 Serum lipase 
 LFT 0.4/0.1/8.3/4.2/13/10/98 
 Tumor markers 
  CA 19-9 <2.50 
  CEA 
  CA-125 
 
 USG  
  Presentation  
Location 
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 
 
CT  
  Presentation         
  Cyst size 
Location  
  Marcocystic 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant 
  Radiologist’s opinion 
 
 Endoscopy  
  Ampulla 
  Extrinsic mass 
 ERCP 
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  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
Operation done Spleen preserving distal pancreatectomy 
 
Operative findings 
 Location body  
 Size not mentioned 
 Benign / malignant 
 Inoperable 
   
Histopathology  
 Type Benign mucinous cystadenoma 
 Benign/malignant benign 
 Margin 
Spleen 
Immune staining 
 
Post-operative complications 
 Pancreatic fistula    present  
 Intra-abdominal abscess 
 Wound infection 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
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Death 
 
Follow up  
 Duration 19 m  
 Recurrence no  
  
   
   
 
 
 
 
 
Cystic neoplasms of the pancreas 
 
Serial No. 12 
Name Sahana Begum 
Age 39 
Gender F 
Hospital Number 592998C 
Diagnosis Solid papillary epithelial neoplasm 
Presenting complaints     Duration 
Asymptomatic 
Pain         3-4 y  
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
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  3-5 cm 
  5-10 cm 
  >10 cm  
 
Investigations 
 Hb 12.7  
 Serum creatinine 0.9 
 Glucose  AC 120 
   PC 164  
Serum amylase  
 Serum lipase 
 LFT0.5/0.2/8.0/4.5/32/34/105 
 Tumor markers 
  CA 19-9 
  CEA 
  CA-125 
 
 USG  
  Presentation  
Location 
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 
CT  
  Presentation 
  Cyst size 8.5 x 7.5 x 5.8 cm 
Location Tail  
  Marcocystic solid  and cystic  
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant 
  Radiologist’s opinion solid cystic papillary neoplasm  
 
 Endoscopy  
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  Ampulla 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
 
Operation done Laparoscopic distal pancreatectomy and splenectomy 
 
Operative findings 
 Location tail  
 Size 10 cm  
 Benign / malignant 
 Inoperable 
   
Histopathology  
 Type Solid papillary epithelial neoplasm 
 Benign/malignant benign 
 Margin  
Spleen congestion 
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess- lesser sac collection  and left peural effusion 
 Wound infection 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
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 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
  
Death 
 
Follow up  
 Duration 43 m  
 Recurrence no  
  
   
   
 
 
 
 
 
Cystic neoplasms of the pancreas 
 
Serial No. 13 
Name Mita Hore  
Age 44 
Gender F 
Hospital Number 812828C 
Diagnosis Mucinous cystadenoma 
Presenting complaints     Duration 
Asymptomatic  
Pain epigastric       4 -5 y  
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency Steatorrhea  
Previous history of pancreatitis 
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Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm    
  5-10 cm 
  >10 cm  
 Splenomegaly 
 
Investigations 
 Hb 10.1 
 Serum creatinine 0.8 
 Glucose  AC 
   PC  
Serum amylase 452 
 Serum lipase 143 
 LFT 1.0/0.2/7.6/4.4/24/11/57 
 Tumor markers  
  CA 19-9 15.4 
  CEA 
  CA-125 
 
 USG  
  Presentation  
Location 
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
 
CT  
  Presentation 
  Cyst size 3.3 x 2.6 cm 
Location body   
  Marcocystic 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
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  Benign x malignant 
Radiologist’s opinion mucinous cystadenoma/carcinoma / 
pseudocyst 
 
 Endoscopy  
  Ampulla  normal    
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
Operation done spleen sparing distal pancreatectomy  
 
Operative findings 
 Location body  
 Size 4 x 4 cm  
 Benign / malignant 
 Inoperable 
   
Histopathology  
 Type Mucinous cystadenoma 
 Benign/malignant benign 
 Margin  
Spleen 
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
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 Wound infection 
 Hemorrhage  present  
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
  
Death 
 
Follow up  
 Duration 27 m  
Recurrence after 13 m completion distal pancreatectomy.  No tumor 
in specimen  
  
   
   
 
 
 
 
 
Cystic neoplasms of the pancreas 
 
Serial No. 14 
Name  Soma Roy 
Age 26 
Gender F 
Hospital Number 546857C  
Diagnosis Mucinous cystadenoma 
Presenting complaints     Duration 
Asymptomatic 
Pain luq        2 y  
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
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Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm  
 
Investigations 
 Hb14.0 
 Serum creatinine 0.7 
 Glucose  AC 100 
   PC  
Serum amylase 118 
 Serum lipase 76 
 LFT 0.8/0.2/8.0/4.2/34/59/147 
 Tumor markers  
  CA 19-9 
  CEA 
  CA-125 
 
 USG  
  Presentation suboptimal  
Location 
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 
 
CT  
  Presentation 
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  Cyst size 5.4 x 2.8 cm  
Location tail  
  Marcocystic 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant infiltration present  
  Radiologist’s opinion cystic neoplasm 
 
 Endoscopy  
  Ampulla normal  
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 73400 
Operation done Distal pancreatectomy and splenectomy  
 
Operative findings 
 Location 6 x 5 cm body and tail  
 Size 
 Benign / malignant 
 Inoperable 
   
Histopathology  
 Type Mucinous cystadenoma 
 Benign/malignant benign 
 Margin  
Spleen congestion 
 99
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection Superficial 
Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
  
Death 
 
Follow up  
 Duration 3m  
 Recurrence no  
  
   
   
 
 
 
 
 
Cystic neoplasms of the pancreas 
 
Serial No. 15 
Name Rumi Sarkar  
Age 34 
Gender F 
Hospital Number 900362C 
Diagnosis Solid pseudopapillary neoplasm 
Presenting complaints     Duration 
Asymptomatic 
Pain upper abdomen discomfort    6 m  
Jaundice 
Nausea 
Vomiting 
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Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 7 x 5 cm  
  >10 cm  
 
Investigations 
 Hb  12.6 
 Serum creatinine 0.8 
 Glucose  AC 112 
   PC 132  
Serum amylase 
 Serum lipase 
 LFT 
 Tumor markers 
  CA 19-9 
  CEA 
  CA-125 
 
 USG  
  Presentation  
Location 
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 101
 
CT  
  Presentation 
  Cyst size 12 x 8 cm 
Location tail  
  Marcocystic 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant 
  Radiologist’s opinion 
 
 Endoscopy  
  Ampulla 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
Operation done Distal pancreatectomy 
 
Operative findings 
 Location tail  
 Size 15 x 15 cm  
 Benign / malignant 
 Inoperable 
   
Histopathology  
 Type Solid Pseudopapillary epithelial neoplasm 
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 Benign/malignant benign 
 Margin Free 
Spleen Congestion 
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
  
Death 
 
Follow up  
 Duration nil 
 Recurrence 
  
   
   
 
 
 
 
 
Cystic neoplasms of the pancreas 
 
Serial No. 16 
Name Sima Biswas 
Age 25 
Gender F 
Hospital Number 897471C 
Diagnosis solid pseudopapillary tumor  
Presenting complaints     Duration 
Asymptomatic 
Pain luq        3m  
 103
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension  prev laparotomy and panc fistula  
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm  
 
Investigations 
 Hb 8.1  
 Serum creatinine 1.9 
 Glucose  AC  
   PC  
Serum amylase 208 
 Serum lipase 319 
 LFT 0.4/0.2/6.7/3.1/23/12/108 
 Tumor markers 
  CA 19-9 
  CEA 
  CA-125 
 
 USG  
  Presentation  
Location 
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
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  Solid component 
  Papillary 
  
 
 
CT  
  Presentation 
  Cyst size 11 x 8.6 x 6.4 cm  
Location body and tail 
  Marcocystic 
  Rim calcification 
  Neoplasm x pseudocyst stranding , splenic vein thrombosis 
  Serous x mucinous 
  Benign x malignant 
  Radiologist’s opinion infected pseudocyst 
 
 Endoscopy  
  Ampulla 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
 
Operation done Distal pancreatectomy ans splenectomy 
 
Operative findings 
 Location 5 x 5 cm  
 Size distal body and tail  
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 Benign / malignant   diaphragmatic rent  
 Inoperable 
   
Histopathology  
 Type Solid cystic pseudopapillary neoplasm 
 Benign/malignant benign 
 Margin free 
Spleen Normal 
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess percutaneous drain placed  
 Wound infection 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
  
Death 
 
Follow up  
 Duration 2m  
 Recurrence no  
  
   
   
 
 
 
 
 
 
 
Cystic neoplasms of the pancreas ip 
 
Serial No. 17 
Name Rebecca George 
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Age 62 
Gender F 
Hospital Number 304532B  
Diagnosis Mucinous cystadenoma  
Presenting complaints     Duration 
Asymptomatic     incidental pickup 
Pain 
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm  
 
Investigations 
 Hb 12.2  
 Serum creatinine 0.9 
 Glucose  AC128 
   PC 190 
Serum amylase  
 Serum lipase 
 LFT 
 Tumor markers 
  CA 19-9 
  CEA 
  CA-125 
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 USG  
  Presentation yes 
Location tail, pseudocyst 
Cyst 6 x 5 cm  
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 
CT  
  Presentation 
  Cyst size 6 x 4 cm  
Location tail , no solid component, MPD not dilated  
  Marcocystic 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant benign  
  Radiologist’s opinion serous cystadenoma 
 
 Endoscopy  
  Ampulla 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
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Operation done Distal pancreatectomy splenectomy 
 
Operative findings 
 Location body and tail  
 Size 
 Benign / malignant 
 Inoperable 
   
Histopathology  
 Type Mucinous cystadenoma 
 Benign/malignant 
 Margin 
Spleen 
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
  
Death 
 
Follow up  
 Duration nil  
 Recurrence 
  
   
   
 
 
 
 
 
Cystic neoplasms of the pancreas 
 109
 
Serial No. 18 
Name Savita Singh 
Age 36 
Gender F 
Hospital Number 036672 D 
Diagnosis Mucinous cystadenoma 
Presenting complaints     Duration 
Asymptomatic 
Pain                    5 years 
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm  
 
Investigations 
 Hb 12.1  
 Serum creatinine 0.6 
 Glucose  AC  
   PC  
Serum amylase 
 Serum lipase 
 LFT 
 Tumor markers 
  CA 19-9 53.1 
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  CEA 1.85 
  CA-125 
 
 USG  
  Presentation  
Location 
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 
CT  
  Presentation 
  Cyst size 9.5 x 8.5 cm  
Location distal body and   tail  
  Marcocystic unilocular  
  Rim calcification 
  Neoplasm x pseudocyst pseudocyst 
  Serous x mucinous 
  Benign x malignant 
  Radiologist’s opinion pseudocyst 
 
 Endoscopy  
  Ampulla 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
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  CA 19-9 
  CA-125 
  Amylase 
 
Operation done Distal pancreatectomy and splenectomy 
 
Operative findings 
 Location  mass body of pancreas  
 Size 10 x 8 cm 
 Benign / malignant 
 Inoperable 
   
Histopathology  
 Type Benign mucinous cystadenoma 
 Benign/malignant benign 
 Margin Free 
Spleen Normal  
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection present  
 Reoperation 
  
Death 
 
Follow up  
 Duration 15 d  
 Recurrence no  
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Cystic neoplasms of the pancreas 
 
Serial No. 19 
Name Sipra Das 
Age 53 
Gender F 
Hospital Number 274084D 
Diagnosis IPMN 
Presenting complaints     Duration 
Asymptomatic 
Pain       8 m  
Jaundice      3 w 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea  
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency steatorrhea 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm tender ruq mass  
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm  
 
Investigations 
 Hb 10.2 
 Serum creatinine 0.7 
 Glucose  AC 111 
   PC 202 
Serum amylase 128 
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 Serum lipase 
 LFT 0.5/0.2/7.8/3.9/73/38/468 
 Tumor markers 
  CA 19-9 307 
  CEA 
  CA-125 
 
 USG  
  Presentation  
Location 
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 
CT  
  Presentation  
  Cyst size4 x 4 x 4 cm  
Location uncinate obstruction  of MPD and CBD  
  Marcocystic 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant loss of fat plane  
  Radiologist’s opinion  malignant neoplasm 
 
 Endoscopy  
  Ampulla gaping major papilla plugged with mucus 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass- MPD dilated in head, body and tail , mural  
  nodules seen  
  Macrocystic septation 
  Honeycomb septation 
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 EUS guided FNAC scanty atypical cells 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
Operation done Whipple procedure 
 
Operative findings 
 Location head  to tail ductal dilatation  
 Size excised till free frozen margin 
 Benign / malignant 
 Inoperable 
   
Histopathology  
 Type IPMN with moderate dysplasia 
 Benign/malignant benign 
 Margin 
Spleen 
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection superficial 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
  
Death 
 
Follow up  
 Duration 15 d  
 Recurrence no  
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Cystic neoplasms of the pancreas 
 
Serial No. 20  
Name Saritha  
Age963338C 
Gender F 
Hospital Number 963338C  
Diagnosis Solid pseudo papillary neoplasm  
Presenting complaints     Duration 
Asymptomatic lump    2 y 
Pain dull dragging     2 y 
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm  15 x 20 cm lump  
 
Investigations 
 Hb 10.3 
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 Serum creatinine 0.7 
 Glucose  AC 102 
   PC  
Serum amylase 
 Serum lipase 
 LFT 
 Tumor markers 
  CA 19-9 13.4 
  CEA 
  CA-125 
 
 USG  
  Presentation  
Location 
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 
 
 
 
CT  
  Presentation 
  Cyst size  
Location body and tail 
  Marcocystic 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant 
  Radiologist’s opinion c Loop GIST 
 
 Endoscopy  
  Ampulla -Normal  
  Extrinsic mass 
 ERCP 
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  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
Operation done whipple  
 
Operative findings 
 Location head  
 Size 15 x 12 cm 
 Benign / malignant 
 Inoperable 
   
Histopathology  
 Type solid pseudopapillary neoplasm 
 Benign/malignant benign 
 Margin free 
Spleen 
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
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Death 
 
Follow up  
 Duration 6 m  
 Recurrence no  
  
   
   
 
 
 
 
 
Cystic neoplasms of the pancreas 
 
Serial No. 30 
Name Angurbala Mandal 
Age 53 
Gender F 
Hospital Number 273358 C 
Diagnosis Serous cystadenoma 
Presenting complaints     Duration 
Asymptomatic 
Pain epigastric burning    4 m 
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
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  3-5 cm 
  5-10 cm 
  >10 cm  10 x 10 cm epigastric mass  
 
Investigations 
 Hb 9.3  
 Serum creatinine 0.7 
 Glucose  AC 
   PC 83  
Serum amylase 90 
 Serum lipase 
 LFT0.8/0.2/8.7/4.6/21/14/138 
 Tumor markers 
  CA 19-9 3.89 
  CEA 
  CA-125 
 
 USG  
  Presentation  
Location tail  
Cyst 6.7 x 5.8 x 4.4 cm 
  Microcyst 
  Macrocyst present 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 
 
 
 
CT  
  Presentation  
  Cyst size 6 x 6 x 7 cm 
Location body and tail  
Marcocystic solid component, calcification 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous mucinous 
  Benign x malignant 
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  Radiologist’s opinion mucinous cystic neoplasm 
 
 Endoscopy  
  Ampulla normal  
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
Operation done distal pancreatectomy and splenectomy 
 
Operative findings  
 Location body and tail 
 Size 10 x 6 cm  
 Benign / 
 Inoperable 
   
Histopathology  
 Type Solid papillary epithelial neoplasm 
 Benign/malignant benign 
 Margin  
Spleen normal  
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection 
 Hemorrhage        
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 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying Ileus 
 Urinary tract infection 
 Reoperation 
  
Death 
 
Follow up  
 Duration 13 m  
 Recurrence no  
  
   
   
 
 
 
 
 
Cystic neoplasms of the pancreas ip 
 
Serial No. 22 
Name Rathinammal 
Age 48 
Gender F 
Hospital Number 789293C  
Diagnosis Mucinous cystadenocarcinoma  
Presenting complaints     Duration 
Asymptomatic 
Pain       6m 
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
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Previous history of pancreatitis Emergency presentation 
 
Examination findings 
 Mass free fluid rupture  
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm  
 
Investigations 
 Hb 14.9  
 Serum creatinine 1.2 
 Glucose  AC 294 
   PC  
Serum amylase 497 
 Serum lipase 526 
 LFT 
 Tumor markers 
  CA 19-9 6.26 
  CEA 0.80 
  CA-125 
 
 USG  
  Presentation  
Location tail 
Cyst 12 x 6 cm  thick wall 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 
 
 
 
CT  
  Presentation 
  Cyst size 12 x 11 x 11 cm 
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Location tail enhancing septation  
  Marcocystic 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant 
  Radiologist’s opinion complicated pseudocyst 
 
 Endoscopy  
  Ampulla 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 3350 
Operation done distal pancreatectomy, splenectomy 
 
Operative findings 
 Location tail 
 Size 10 x 9 cm  
 Benign / malignant 
 Inoperable adherent to tr mesocolon 
   
Histopathology  
 Type Mucinous cystadenocarcinoma 
 Benign/malignant malignant 
 Margin free  
Spleen normal 
Immune staining 
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Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection burst  
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation burst  
   Enterocutaneous fistula, stroke 
  
Death 
 
Follow up  
 Duration nil  
 Recurrence 
  
   
   
 
 
 
 
 
Cystic neoplasms of the pancreas 
 
Serial No. 23 
Name Urmimala Mukherjee 
Age 54 
Gender F 
Hospital Number 165335D  
Diagnosis Acinar cell carcinoma 
Presenting complaints     Duration 
Asymptomatic 
Pain 
Jaundice 
Nausea 
Vomiting       1 yr 
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Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 8 x 7 cm epigastric 
  >10 cm  
 
Investigations 
 Hb 10.3  
 Serum creatinine 0.7 
 Glucose  AC82 
   PC 99 
Serum amylase238 
 Serum lipase  
 LFT 0.5/0.3/6.5/2.8/25/18/152 
 Tumor markers 
  CA 19-9 30.0 
  CEA 8.5 
  CA-125 
 
 USG  
  Presentation  
Location 
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
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CT  
  Presentation  
  Cyst size 8x12x12 cm 
Location body and tail 
  Marcocystic 
  Rim calcification vascular  
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant benign 
Radiologist’s opinion islet cell tumor solid pseudo papillary 
tumor 
      
 Endoscopy  
  Ampulla normal  
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
Operation done distal pancreatecomy and splenectomy 
 
Operative findings 
 Location body and tail 
 Size 15 x 12 cm  
 Benign / malignant benign 
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 Inoperable 
   
Histopathology  
 Type Acinar cell carcinoma 
 Benign/malignant malignant 
 Margin free 
Spleen congestion 
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
  
Death 
 
Follow up  
 Duration nil 
 Recurrence 
  
   
   
 
 
 
 
 
 
 
Cystic neoplasms of the pancreas 
 
Serial No. 24 
Name Nirmal Kumar Sinha 
Age 43 
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Gender M 
Hospital Number 083790D  
Diagnosis Mucin producing adenocarcinoma 
Presenting complaints     Duration 
Asymptomatic 
Pain luq          5m 
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue      Loss of weight  
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm  
 
Investigations 
 Hb 14.2 
 Serum creatinine 0.9 
 Glucose  AC 108 
   PC 168 
Serum amylase 92 
 Serum lipase 30 
 LFT 0.4/0.2/7.9/4.7/22/29/82 
 Tumor markers 
  CA 19-9 
  CEA 
  CA-125 
 
 USG  
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  Presentation  
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 
 
CT  
  Presentation 
  Cyst size solid and cystic areas  
Location body and tail  
  Marcocystic 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant 
  Radiologist’s opinion no opinion 
 
 Endoscopy  
  Ampulla 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
Operation done distal pancreatectomy splenectomy 
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Operative findings 
 Location body and tail 
 Size  
 Benign / malignant 
 Inoperable 
   
Histopathology  
 Type Mucin producing adenocarcinoma  
 Benign/malignant malignant 
 Margin free  
Spleen congestion 
Nodal mets present 
 
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
  
Death 
 
Follow up  
 Duration 10 m  
 Recurrence no  
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Cystic neoplasms of the pancreas ip 
 
Serial No. 25  
NameTumpa Barua  
Age 18 
Gender F 
Hospital Number 172706D 
Diagnosis Benign cystic lesion 
Presenting complaints     Duration 
Asymptomatic Right adnexal mass 
Pain        2m 
Jaundice 
Nausea 
Vomiting      2m 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension                               
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm palpable 26 weeks 
  >10 cm  
 
Investigations12 
 Hb 13.4  
 Serum creatinine 0.5 
 Glucose  AC 
   PC  
Serum amylase  
 Serum lipase 
 LFT 
 Tumor markers 
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  CA 19-9 
  CEA 
  CA-125 50.8 
 
 USG  
  Presentation  
Location 
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 
 
 
 
CT  
  Presentation  
  Cyst size 
Location  
  Marcocystic 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant 
  Radiologist’s opinion 
 
 Endoscopy  
  Ampulla 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
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 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
Operation done mesopancreatectomy 
 
Operative findings 
 Location 20 x 15 cm  
 Size neck  
 Benign / malignant 
 Inoperable 
   
Histopathology  
 Type benign cystic lesion 
 Benign/malignant benign   
 Margin 
Spleen 
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
 Gram neg sepsis ++ 
Death 
 
Follow up  
 Duration 15 days 
 Recurrence no  
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Cystic neoplasms of the pancreas 
 
Serial No. 30 
Name Angurbala Mandal 
Age 53 
Gender F 
Hospital Number 273358 C 
Diagnosis serous cystadenoma 
Presenting complaints     Duration 
Asymptomatic 
Pain epigastric burning   4y 
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm  
 
Investigations 
 Hb 12.9 
 Serum creatinine  0.7 
 Glucose  AC 
   PC 114  
Serum amylase 193 
 135
 Serum lipase 
 LFT 0.6/0.2/7.7/4.1/28/37/79 
 Tumor markers 
  CA 19-9 4.5  
  CEA 
  CA-125 
 
 USG  
  Presentation  
Location tail  
Cyst  6 x 6 x 4 cm  
  Microcyst 
  Macrocyst multiseptated cystic with solid components  
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 
 
 
 
CT  
  Presentation  
  Cyst size 6 x 6 x 7 cmcm 
Location body and tail  
Marcocystic solid compnonent, calcification 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous mucinous 
  Benign x malignant 
  Radiologist’s opinion mucinous cystic neoplasm 
 
 Endoscopy  
  Ampulla 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
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  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
Operation done distal pancreatectomy and splenectomy 
 
Operative findings  
 Location body and tail 
 Size 10 x 6 cm  
 Benign / 
 Inoperable 
   
Histopathology  
 Type Serous cystadenoma 
 Benign/malignant benign 
 Margin  
Spleen normal  
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection 
 Hemorrhage       ileus 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
  
Death 
 
Follow up  
 Duration 
 137
 Recurrence 
  
   
   
 
 
 
 
 
Cystic neoplasms of the pancreas 
 
Serial No.32 
Name Maya Maity  
Age 28 
Gender F 
Hospital Number 977822c 
Diagnosis teratoma 
Presenting complaints     Duration 
Asymptomatic  
Pain upper    5 yrs  
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm 10 x 10 cm epigastric  
Spleen 2 cm  
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Investigations 
 Hb 10  
 Serum creatinine  
 Glucose  AC    PC   
Serum amylase 70 
 Serum lipase 
 LFT  
 Tumor markers 
  CA 19-9 <2.50 
  CEA 61.2 
  CA-125 
 
 USG  
  Presentation  
Location 
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 
 
 
 
CT  
  Presentation  
  Cyst size 21 x 16 x 11 cm  
Location tail lesser sac splenic vein thrombosis  
  Marcocystic 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant 
  Radiologist’s opinion dermoid 
 
 Endoscopy  
  Ampulla 
  Extrinsic mass 
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 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
Operation done distal panacreatectomy splenectomy  
 
Operative findings 
 Location body and tail  
 Size 17 x 15 cm  
 Benign / malignant  
 Inoperable 
   
Histopathology  
 Type mature cystic teratoma  
 Benign/malignant benign 
 Margin 
Spleen 
Immune staining 
 
Post-operative complications 
 Pancreatic fistula 
 Intra-abdominal abscess 
 Wound infection 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
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Death 
 
Follow up  
 Duration 11 months 
 Recurrence no  
  
   
   
 
 
 
 
 
Cystic neoplasms of the pancreas 
 
Serial No.33 
Name Baby A.   
Age 17 
Gender F 
Hospital Number 327356 C 
DiagnosisSPT 
Presenting complaints     Duration 
Asymptomatic  
Pain upper and  lump       3m  
Jaundice  
Nausea 
Vomiting 
Jaundice 
Constipation 
Diarrhea 
Abdominal distension 
Fatigue    diagnosed hydatid cyst, underwent lap bx  
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
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  2-3 cm 
  3-5 cm 4 x4 cm 
  5-10 cm 
  >10 cm   
 
Investigations 
 Hb 12  
 Serum creatinine  
 Glucose  AC    PC   
Serum amylase  
 Serum lipase 
 LFT 0.4/0.2/7.6/4.6/25/13/112 
 Tumor markers  
  CA 19-9  
  CEA  
  CA-125 
 
 USG  
  Presentation hydatid cyst liver   
Location  
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 
 
 
 
CT  
  Presentation  
  Cyst size  
Location  
  Marcocystic 
  Rim calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant 
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  Radiologist’s opinion 
 Endoscopy  
  Ampulla 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
Operation done PPPD 
 
Operative findings 
 Location Head  
 Size 10 x 10 cm  
 Benign / malignant  
 Inoperable 
   
Histopathology  
 Type Solid cystic neoplasm 
 Benign/malignant  
 Margin 
Spleen 
Immune staining 
 
Post-operative complications 
 Pancreatic fist 
 
al abscess 
 Wound infection 
 Hemorrhage 
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 Aspiration pneumonia 
 Deep vein thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
  
Death 
 
Follow up  
 Duration 25 m  
 Recurrence no  
  
   
   
 
 
 
 
 
 
 
 
 
 
Cystic neoplasms of the pancreas 
 
Serial No. 29 
Name Sofia Hima Bindu 
Age 34 
Gender F 
Hospital Number 917093C  
Diagnosis Solid pseudopapillary tumor 
Presenting complaints     Duration 
Asymptomatic 
Pain upper       6m 
Jaundice 
Nausea 
Vomiting 
Jaundice 
Constipation 
 144
Diarrhea 
Abdominal distension 
Fatigue 
Early satiety 
Pancreatic exocrine insufficiency 
Previous history of pancreatitis 
 
Examination findings 
 Mass 
  <2 cm 
  2-3 cm 
  3-5 cm 
  5-10 cm 
  >10 cm  
 
Investigations 
 Hb 10.1  
 Serum creatinine 0.7 
 Glucose  AC  
   PC  
Serum amylase 96 
 Serum lipase 
 LFT 
 Tumor markers 
  CA 19-9 8.71 
  CEA 
  CA-125 
 
 USG  
  Presentation  
Location 
Cyst 
  Microcyst 
  Macrocyst 
  Dilated pancreatic duct 
  Solid component 
  Papillary 
  
 
CT  
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  Presentation 
  Cyst size 5 x 5 x 2.8 cm 
Location body 
  Marcocystic 
  Rim calcification chunky calcification 
  Neoplasm x pseudocyst 
  Serous x mucinous 
  Benign x malignant malignant 
  Radiologist’s opinion malignant 
 
 Endoscopy  
  Ampulla 
  Extrinsic mass 
 ERCP 
  Communication with the cyst cavity 
  
 EUS 
  Adjacent mass 
  Macrocystic septation 
  Honeycomb septation 
  
 EUS guided FNAC 
  
 Tumor markers in cyst fluid 
  CEA 
  CA 19-9 
  CA-125 
  Amylase 
Operation done Subtotal pancreatectomy and splenectomy 
 
Operative findings 
 Location neck 
 Size 5 x 4 cm  
 Benign / malignant 
 Inoperable 
   
Histopathology  
 Type solid pseudopapillary neoplasm  
 Benign/malignant benign  
 Margin free  
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Spleen congestion 
Immune staining 
 
Post-operative complications 
 Pancreatic fistula present  
 Intra-abdominal abscess 
 Wound infection present 
 Hemorrhage 
 Aspiration pneumonia 
 Deep vein thrombosis smv thrombosis 
 Delayed gastric emptying 
 Urinary tract infection 
 Reoperation 
  
Death 
 
Follow up  
 Duration 11m  
 Recurrence no  
  
   
   
 
 
 
 
 
 
